Edition:
United Kingdom

Neuralstem Inc (CUR.OQ)

CUR.OQ on NASDAQ Stock Exchange Capital Market

1.89USD
7:41pm GMT
Change (% chg)

$-0.04 (-2.07%)
Prev Close
$1.93
Open
$1.88
Day's High
$1.96
Day's Low
$1.77
Volume
99,486
Avg. Vol
204,705
52-wk High
$6.58
52-wk Low
$0.89

Latest Key Developments (Source: Significant Developments)

Neuralstem Q3 loss per share $0.01
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Neuralstem Inc :Neuralstem reports third quarter 2017 fiscal results and provides clinical and business update.Q3 loss per share $0.01.Neuralstem - ‍expect to provide detailed update on corporate strategy after post-phase 2 meeting with fda in h1 2018​.Neuralstem Inc - ‍ recent financing further extended co's cash runway to sufficiently support continued research on NSI-189 and to support operations​.Neuralstem Inc - ‍plans to meet with U.S. Food and Drug Administration in first half of 2018 to discuss clinical development path for NSI-189​.  Full Article

Neuralstem says filed for a non-timely 10-Q - SEC filing
Tuesday, 9 Aug 2016 

Neuralstem Inc : Says it has filed for a non-timely 10-Q - SEC filing . Says unable to file quarterly report on form 10-Q for period ended June 30, 2016 due to difficulty in obtaining required information Source: (http://bit.ly/2b0Z3SN ) Further company coverage: [CUR.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Neuralstem announces corporate reorganization
Friday, 20 May 2016 

Neuralstem Inc : Neuralstem announces plan of reorganization to further align business with strategic intent . Corporate reorganization to further align company's resources on advancing NSI-189 Neurogenic small molecule program . Says corporate reorganization includes a workforce reduction across all divisions . Reorganization to align resources on advancing NSI-189 neurogenic small molecule program, currently in a phase 2 clinical trial .Reorganization also to continue to pursue collaborations for NSI-566 stem cell therapy program that will expedite clinical development.  Full Article

Neuralstem entered into agreement to sell 2.7 mln shares
Thursday, 12 May 2016 

Neuralstem Inc : Entered into agreement to sell 2.7 million shares of stock and warrants to purchase 2.7 million shares of common stock in private placement .Securities are being sold in private offering at a price of $0.40 per one share of common stock and one common stock purchase warrant.  Full Article

Neuralstem says first patient enrolled in Phase 2 trial in major depressive disorder
Thursday, 12 May 2016 

Neuralstem Inc - : Neuralstem expects to report results in second half of 2017 . Neuralstem Inc says there were no significant adverse effects in phase 1b safety trial data in patients with mdd .Neuralstem announces first patient enrolled in phase 2 clinical trial in major depressive disorder.  Full Article

Neuralstem posts Q1 loss per share $0.07
Monday, 9 May 2016 

Neuralstem Inc : Q1 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S . Neuralstem reports fiscal first quarter 2016 results and business update .Q1 loss per share $0.07.  Full Article

Neuralstem Inc prices underwritten public offering of securities
Tuesday, 3 May 2016 

Neuralstem Inc:Pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $0.40 per share.Offering is expected to close on May 6.Gross proceeds of the offering are expected to be approximately $8 million.Intends to use the net proceeds from this underwritten offering to fund regulatory, pre-clinical and clinical activities and general corporate purposes, including working capital and the repayment of debt.  Full Article

Neuralstem Inc appoints Richard Daly as President and CEO
Tuesday, 16 Feb 2016 

Neuralstem Inc:Appoints Richard Daly as president and chief executive officer.Daly succeeds Richard Garr as CEO.Says daly is also being appointed to the company's board of directors.  Full Article

BRIEF-Neuralstem Q3 loss per share $0.01

* Neuralstem reports third quarter 2017 fiscal results and provides clinical and business update